Helius Medical Technologies, Inc. to Present at the Noble Capital Markets 17th Annual Small & Microcap Investor Conference

Rhea-AI Summary

Helius Medical Technologies, a neurotech company, will participate in the Noble Capital Markets 17th Annual Small & Microcap Investor Conference on January 19-20, 2021. Management's presentation is scheduled for January 19 at 11:15 a.m. ET. A live audio webcast will be accessible following free registration on the Noble conference website. Helius focuses on developing non-invasive technologies for neurological wellness, including the Portable Neuromodulation Stimulator (PoNS™), currently under FDA review.

NEWTOWN, Pa., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Noble Capital Markets 17th Annual Small & Microcap Investor Conference, which is being held virtually from January 19th-20th. Management will present on Tuesday, January 19th at 11:15 a.m. Eastern Time.

A live audio webcast of the conference presentation will be available on the Noble conference website following free registration: https://www.nobleconference.com/register/investor-guest. An archive of the webcast will be available following the conference under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.

Investor Relations Contact:

Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell
investorrelations@heliusmedical.com

FAQ

What is the date of HSDT's presentation at the Noble Capital Markets Conference?

Helius Medical Technologies (HSDT) will present on January 19, 2021, at 11:15 a.m. ET.

Where can I watch HSDT's conference presentation?

You can watch HSDT's conference presentation by registering on the Noble conference website.

What is the Portable Neuromodulation Stimulator (PoNS™) by HSDT?

PoNS™ is a non-invasive medical device for treating gait deficits related to multiple sclerosis and balance issues from traumatic brain injury.

Is the PoNS™ device available for purchase in the U.S.?

Currently, the PoNS™ device is not commercially available in the United States as it is under FDA review.

What is the focus of Helius Medical Technologies?

Helius Medical Technologies focuses on neurological wellness and developing non-invasive technologies to enhance brain healing.